OTIC Otonomy, Inc.

13.10
0  0%
Previous Close 13.15
Open 13.05
Price To book 2.06
Market Cap 396.35M
Shares 30,256,000
Volume 117,846
Short Ratio 10.58
Av. Daily Volume 202,828

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
OTO-311
Tinnitus
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
OTO-104 AVERTS-1 and AVERTS-2
Ménière's disease
Phase 2 trial completed October 2016. End of Phase 2 meeting planned with FDA 1H 2017.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Phase 3 trial met primary endpoint - January 5, 2017. sNDA filing to be submitted 1H 2017.
OTIPRIO
Acute otitis externa

Latest News

  1. OTONOMY, INC. Financials
  2. Otonomy reports 4Q loss
  3. Otonomy reports 4Q loss
  4. Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  5. OTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  6. Q4 2016 Otonomy Inc Earnings Release - After Market Close
  7. Otonomy to Present at Cowen and Company Health Care Conference
  8. Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
  9. Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
  10. OTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  11. Otonomy Provides Corporate and Product Pipeline Update
  12. Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : January 6, 2017
  13. Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
  14. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  15. Otonomy's ear infection drug succeeds in late-stage trial
  16. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  17. What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO)
  18. Otonomy to Present at the J.P. Morgan Healthcare Conference
  19. Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : December 19, 2016
  20. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 16, 2016